ABPI comment on NIHR framework for restarting paused research

21 May 2020 Posted in News by Press Office

The NIHR has set out a framework for resuming health research that was paused as a result of the COVID-19 pandemic. 

It’s critical that vital scientific research can continue so that new treatments can be developed for patients. Dr Sheuli Porkess

In response to today's announcement, Dr Sheuli Porkess, ABPI's Executive Director of Research, Medical and Innovation said: 

“This framework is a key first step in restarting clinical trials that have been paused due to COVID-19. It’s critical that vital scientific research can continue so that new treatments can be developed for patients.

“The health of patients must be our priority. The pharmaceutical industry will continue to work in partnership with the NHS and the Government to get the UK’s research ecosystem back up and running.”

 

TAGS
  • Clinical research

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​